Blood Testing on TRT: Why It Matters More Than You Think
Starting testosterone replacement therapy without a plan for regular bloodwork is like driving cross-country without a fuel gauge. You might get where you are going, but you are flying blind and you will not know something is wrong until it becomes a real problem. This video lays out twelve rules for monitoring your health while on TRT, and the principles apply whether you are working with a clinic, an endocrinologist, or managing your therapy with a knowledgeable primary care provider.
The foundation of responsible TRT is establishing thorough baselines before you start. You need to know where your numbers were before testosterone entered the picture, because those baselines become the reference point for every decision you make going forward. A lab panel drawn after you have already started therapy is useful, but it cannot tell you what your natural state was. That information is gone once exogenous testosterone is in your system.
At minimum, baseline labs should include total testosterone, free testosterone, estradiol (sensitive assay), complete blood count (CBC) with hematocrit and hemoglobin, thorough metabolic panel, lipid panel, PSA (for men over 40 or with prostate cancer family history), LH, FSH, SHBG, and prolactin. This gives you a complete snapshot of your hormonal, metabolic, and hematological status before any intervention.
The Twelve Rules for Lab Monitoring on TRT
The first several rules center on timing and consistency. When you draw blood relative to your last injection matters enormously. Testosterone levels on injection-based protocols (cypionate, enanthate) follow a predictable curve: they peak 24-48 hours after injection and decline over the following days. Drawing blood at peak gives you one number. Drawing at trough (the day before your next injection) gives you a very different number. Neither is wrong, but they tell you different things, and you need to be consistent about when you test so your results are comparable over time.
Most practitioners recommend testing at trough, which captures the lowest point in your cycle and ensures your levels stay adequate even at their lowest. If your trough level is within the target range, you know you are covered throughout the entire injection cycle. Testing at random points between injections introduces variability that makes interpretation difficult.
Hematocrit monitoring is one of the most important and most overlooked aspects of TRT management. Testosterone stimulates erythropoiesis (red blood cell production), which means hematocrit and hemoglobin tend to rise on TRT. A modest increase is normal and expected. But if hematocrit climbs above 52-54%, the blood becomes increasingly viscous, raising the risk of blood clots, stroke, and cardiovascular events. This is not a theoretical risk. It is one of the most common reasons men have to adjust their TRT dose, switch to a different protocol, or add therapeutic phlebotomy (blood donation or blood draws to reduce hematocrit).
Estradiol: The Hormone Men Need to Stop Ignoring
Estradiol management on TRT is one of the most contested topics in the hormone optimization space. Testosterone converts to estradiol via the aromatase enzyme, and on TRT, estradiol levels typically rise proportionally to the testosterone dose. Some degree of estradiol elevation is normal and even beneficial. Men need estrogen for bone health, cardiovascular protection, brain function, and libido. The goal is not to eliminate estrogen but to keep it in a range that supports these functions without causing unwanted effects.
Symptoms of estradiol being too high include water retention, moodiness, breast tissue sensitivity or growth (gynecomastia), and decreased libido. Symptoms of estradiol being too low (often from excessive aromatase inhibitor use) include joint pain, dry skin, low libido, fatigue, and depression. Both extremes are problematic, and the only way to know where you stand is through the sensitive estradiol assay (LC/MS method), not the standard immunoassay which is less accurate in men.
The use of aromatase inhibitors (AIs) like anastrozole on TRT is increasingly controversial. Earlier TRT protocols frequently paired testosterone with an AI to keep estradiol in check. Current thinking among many experienced practitioners is that AIs should be used sparingly, if at all, and that adjusting the testosterone dose or injection frequency is a better first-line approach to managing estradiol. Crashing estrogen with an AI often creates more problems than it solves.
PSA, Liver Enzymes, and Lipid Monitoring
PSA (prostate-specific antigen) monitoring is standard practice for men on TRT, particularly those over 40. TRT does not cause prostate cancer based on current evidence, but it can stimulate the growth of existing prostate tissue, including any undetected cancer that might already be present. A baseline PSA and regular follow-up testing (every 6-12 months) allow you to track trends. A rapid rise in PSA, even if the absolute number is within the normal range, warrants further evaluation.
Liver function tests (AST, ALT) should be monitored periodically, particularly in men using oral testosterone formulations (like oral testosterone undecanoate) or any concurrent medications that are hepatically metabolized. Injectable testosterone cypionate and enanthate have minimal liver impact, but the test is still worth including in your regular panels as a general health marker.
Lipid panels deserve attention because testosterone can affect cholesterol metabolism. TRT tends to lower HDL cholesterol in some individuals, which is not ideal from a cardiovascular perspective. Monitoring lipids every 6-12 months allows you to catch any adverse trends early and address them through dietary changes, supplementation (omega-3s, fiber), or medication if needed.
Testing Frequency: A Practical Schedule
During the initial optimization phase (the first 3-6 months of TRT), labs should be checked every 6-8 weeks. This allows enough time for levels to stabilize after dose adjustments while catching problems before they become serious. Once you are dialed in on a stable protocol with consistent bloodwork results, testing can move to every 3-6 months for routine monitoring.
Any time you change your dose, switch injection frequency, add or remove a medication (like an AI or HCG), or experience new symptoms, labs should be drawn 4-6 weeks after the change. This gives you data to assess the impact of the change rather than guessing.
The Rules in Practice
Following these twelve rules consistently is what separates a well-managed TRT protocol from a risky one. The men who run into serious problems on TRT are overwhelmingly those who are not testing regularly, who ignore rising hematocrit, who crash their estrogen with excessive AI use, or who dose based on how they feel rather than what their bloodwork shows. Feelings matter, but they are unreliable indicators of what is happening biochemically.
The cost of regular testing is one of the most common objections, and it is valid. Lab work adds up, especially if you are paying out of pocket. But relative to the cost of TRT itself and the potential cost of managing a complication from unmonitored therapy, regular testing is the cheapest insurance you can buy. Services like direct-to-consumer lab ordering (Marek Health, Ulta Lab Tests, DiscountedLabs) have made thorough panels more accessible and affordable than they were even a few years ago.
Ultimately, these rules come down to one principle: you cannot manage what you do not measure. TRT is a powerful intervention with real benefits and real risks. The benefits are maximized and the risks are minimized when you have data guiding every decision.
Advanced Monitoring: Going Beyond the Basics
For men who have been on TRT for longer than a year and have a stable protocol, expanding the monitoring panel to include additional markers can provide deeper insight. Thyroid function (TSH, free T4, free T3) should be checked annually at minimum because testosterone and thyroid hormones interact, and changes in one can affect the other. Vitamin D, ferritin, and homocysteine are also worth tracking annually as they influence energy, mood, and cardiovascular risk in ways that complement the primary TRT-related markers.
Cardiac screening deserves consideration for men on long-term TRT, particularly those over 45 or with cardiovascular risk factors. A coronary calcium score (CAC) provides a direct measurement of arterial plaque burden and can be repeated every 3-5 years to track progression. An echocardiogram establishes baseline cardiac structure and function and can detect early changes in ventricular wall thickness or function that might be related to prolonged supraphysiological hormone exposure.
DHEA-S is a marker that often gets overlooked in TRT monitoring. Exogenous testosterone can suppress DHEA production through HPG axis suppression, and low DHEA-S has independent associations with mood, immune function, and cardiovascular risk. Some practitioners add low-dose DHEA to TRT protocols to maintain physiological adrenal androgen levels, with periodic DHEA-S testing to verify appropriate dosing.
The role of genetics in TRT response is emerging as an area of clinical interest. Variations in the androgen receptor gene (specifically the CAG repeat length), aromatase gene (CYP19A1), and 5-alpha reductase gene (SRD5A2) influence how individuals respond to testosterone, how much estrogen they produce, and how much DHT is generated. While genetic testing for TRT optimization is not yet standard practice, it may become a routine part of initial evaluation as our understanding of pharmacogenomics in hormone therapy deepens.
Ultimately, the twelve rules described in this video distill down to one overarching principle: informed, data-driven management is what makes TRT safe and effective over the long term. The men who thrive on TRT decades into therapy are the ones who treat monitoring as a non-negotiable part of the protocol, not as an optional add-on. The blood draw is the cost of responsible testosterone management, and it is a cost that pays for itself many times over in complications avoided and outcomes optimized.